Efficacy and safety of rituximab in multiple sclerosis: Experience from a developing country

•MS is increasingly being diagnosed in developing countries like India.•Anti B cell therapy with rituximab appears to be an effective strategy in resource limited settings where low cost generic brands of rituximab are available.•Rituximab infusion reactions were minimal with a slow infusion protoco...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Multiple sclerosis and related disorders 2020-08, Vol.43, p.102210-102210, Article 102210
Hauptverfasser:	Mathew, Thomas, John, Saji K., Kamath, Vikram, Murgod, Uday, Thomas, Kurian, Baptist, Anita Angela, Therambil, Manjusha, Shaji, Asha, Nadig, Raghunandan, Badachi, Sagar, Souza, Delon D., Shivde, Sonia, Avati, Amrutha, Sarma, G.R.K., Sharath Kumar, G.G., Deepalam, Saikanth, Parry, Gareth J.
Format:	Artikel
Sprache:	eng
Schlagworte:	B cell therapy Developing Countries Humans Immunologic Factors - adverse effects India Multiple sclerosis Multiple Sclerosis - drug therapy PPMS Rituximab Rituximab - adverse effects RRMS
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!